Glaukos (GKOS)
(Delayed Data from NYSE)
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal
by Zacks Equity Research
Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).
Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny
Genomic Health (GHDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.
Becton, Dickinson Launches BD Resolve Early Access Program
by Zacks Equity Research
Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.
Medtronic (MDT) Adds New Tools, Expands Coronary Suite
by Zacks Equity Research
Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance
by Zacks Equity Research
Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.
Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that it has won a competitive bid in Shanghai.
STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?
by Zacks Equity Research
On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).
Mead Johnson-Reckitt Benckiser Mega Deal: A Strategic Fit?
by Zacks Equity Research
Pediatric nutrition manufacturer Mead Johnson Nutrition Company (MJN) recently announced an agreement to be acquired by British consumer-products maker, Reckitt Benckiser Group plc.
Cerner (CERN) Q4 Earnings Meet, Revenues Miss Estimates
by Zacks Equity Research
Cerner Corp(CERN) reported adjusted fourth-quarter 2016 earnings of 57 cents per share, in line with the Zacks Consensus Estimate.
NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.
Will Glaukos (GKOS) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Glaukos Corp (GKOS).
Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag
by Zacks Equity Research
On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).
Zimmer Biomet (ZBH) Launches Subchondroplasty Procedure
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the musculoskeletal healthcare space, recently announced the global launch of its Subchondroplasty (SCP) Procedure.
CVS Health (CVS) Beats on Q4 Earnings, Retains '17 View
by Zacks Equity Research
CVS Health Corporation (CVS) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $1.71, up 11.8% year over year.
Quest Diagnostics Partners with Veracyte for Cancer Testing
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).
Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.
Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut
by Zacks Equity Research
Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.
Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.
Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.
Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.